Strategic Integration DORC is now integrated into ZEISS Medical Technology offerings following a collaboration with the ZEISS group, presenting a cross-sell opportunity to ZEISS customers and an expanded product ecosystem for ophthalmic surgery.

Product Leadership Continued innovation with EVA NEXUS and TissueBlue positions DORC as a technology-rich supplier for retina and vitreoretinal procedures, suggesting opportunities to upsell advanced visualization, staining, and efficiency tools to high-volume centers.

Regulatory Milestones Successful regulatory approvals across jurisdictions (FDA for TissueBlue and Health Canada clearance) emphasize reliability and global reach, indicating potential for expanding distribution through new regional partners and hospitals seeking compliant solutions.

Global Partnerships Existing distributor network and recent expansions in Greece and Cyprus signal readiness to scale with regional partners; sales development should target additional high-volume ophthalmic centers and governments seeking standardized surgical accuracy.

Financial Opportunity Revenue range and substantial funding indicate capacity for larger deals; align offerings with mid-market ophthalmic clinics and regional distributors to capture share in automated instruments, consumables, and compatible liquids.